Insulin as a bridge between type 2 diabetes and Alzheimer disease – How anti-diabetics could be a solution for dementia

Insulin as a bridge between type 2 diabetes and Alzheimer disease – How anti-diabetics could be a solution for dementia

Type 2 diabetes (T2D) and Alzheimer disease (AD) are two major health issues nowadays. T2D is an ever increasing epidemic, affecting millions of elderly people worldwide, with major repercussions in the patients’ daily life. This is mostly due to its chronic complications that may affect brain and c...

Full description

Bibliographic Details
Main Authors:	Inês eSebastião, Emanuel eCandeias, Maria S Santos, Catarina R. Oliveira, Paula I Moreira, Ana I Duarte
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2014-07-01
Series:	Frontiers in Endocrinology
Subjects:	Alzheimer Disease Brain anti-type 2 diabetes compounds exendin-4 incretins/glucagon-like peptide-1/glucagon-like peptide-1 receptor insulin/insulin receptor signaling
Online Access:	http://journal.frontiersin.org/Journal/10.3389/fendo.2014.00110/full

Similar Items

Treatment with Glucagon-Like Peptide-1 Analogues — a Breakthrough in Diabetes Mellitus Type 2 Therapy
by: V.L. Orlenko, et al.
Published: (2014-05-01)

The associations of incretin hormone concentration with gestational diabetes mellitus
by: Tatiana V. Saprina, et al.
Published: (2016-04-01)

Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications
by: Meike eKörner, et al.
Published: (2012-12-01)

Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
by: Gagik R. Galstyan, et al.
Published: (2017-10-01)

Secretion of incretin hormones in people having risk factors for type 2 diabetes mellitus
by: E A Shestakova, et al.
Published: (2014-10-01)

New Potential Targets of Glucagon-Like Peptide 1 Receptor Agonists in Pancreatic β-Cells and Hepatocytes
by: Won-Young Lee
Published: (2017-02-01)

Pleiotropic effects of incretins
by: Vishal Gupta
Published: (2012-01-01)

Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
by: Howell R, et al.
Published: (2019-04-01)

Renal experiences of bariatric surgery in patients with type 2 diabetes mellitus
by: I I Larina, et al.
Published: (2018-10-01)

In Tune with the World Trends: Clinical Aspects of Liraglutide Use in Combination with Insulin in Patients with Diabetes Mellitus (Literature Review and Clinical Observations)
by: O.V. Korpacheva-Zinych, et al.
Published: (2016-10-01)

The emerging role of incretins in the pathophysiology of insulin resistance in type 1 diabetes.
by: Gorana Mirošević, et al.
Published: (2017-09-01)

Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
by: Nina A. Petunina, et al.
Published: (2018-10-01)

Pharmalogical effects and results of clinical trials of the first incretinomimetic exenatide
by: Alexander Sergeevich Ametov, et al.
Published: (2011-09-01)

Glucagon‐like peptide‐1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLP‐1 receptors
by: Jonas Ronn, et al.
Published: (2017-12-01)

An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass
by: Suk Chon, et al.
Published: (2016-04-01)

Association of glucagon‐like peptide‐1 receptor‐targeted imaging probe with in vivo glucagon‐like peptide‐1 receptor agonist glucose‐lowering effects
by: Takaaki Murakami, et al.
Published: (2020-11-01)

Exendin-4 for Parkinson's disease
by: Felipe de Jesús Esparza-Salazar, et al.
Published: (2021-01-01)

Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists
by: Maria Lucey, et al.
Published: (2020-07-01)

Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?
by: Rodrigo Oliveira Moreira, et al.
Published: (2018-04-01)

Glycemic and Metabolic Effects of Two Long Bouts of Moderate-Intensity Exercise in Men with Normal Glucose Tolerance or Type 2 Diabetes
by: Saeed Reza Eshghi, et al.
Published: (2017-07-01)

The Essential Role of Pancreatic α-Cells in Maternal Metabolic Adaptation to Pregnancy
by: Dzyuba, B., et al.
Published: (2022)

Incretins today: multiple effects and therapeutic potential
by: Oksana V. Tsygankova, et al.
Published: (2019-04-01)

Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury
by: Miaad Bader, et al.
Published: (2019-04-01)

Glucagon-like peptide-1 analogues: An overview
by: Vishal Gupta
Published: (2013-01-01)

Novel Site-Specific Fatty Chain-Modified GLP-1 Receptor Agonist with Potent Antidiabetic Effects
by: Xia Zhong, et al.
Published: (2019-02-01)

Activation of GLP-1 Receptor Promotes Bone Marrow Stromal Cell Osteogenic Differentiation through β-Catenin
by: Jingru Meng, et al.
Published: (2016-04-01)

Effect of Pro-Kinetic Drugs on Post –Prandial Glycaemic Surge in Type 2 Diabetic Patients
by: Asim Zulfiqar
Published: (2012-12-01)

Dissociation of GLP-1 and insulin association with food processing in the brain: GLP-1 sensitivity despite insulin resistance in obese humans
by: Martin Heni, et al.
Published: (2015-12-01)

The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date
by: Antza C, et al.
Published: (2019-08-01)

Dipeptidyl Peptidase (DPP)-IV Inhibitors with Antioxidant Potential Isolated from Natural Sources: A Novel Approach for the Management of Diabetes
by: Anand-Krishna Singh, et al.
Published: (2021-06-01)

Expression of Glucagon-Like Peptide 1 Receptor during Osteogenic Differentiation of Adipose-Derived Stem Cells
by: Yun Kyung Jeon, et al.
Published: (2014-12-01)

Grape powder attenuates the negative effects of GLP-1 receptor antagonism by exendin-3 (9-39) in a normoglycemic mouse model
by: Haufe, Thomas Carl
Published: (2017)

Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity
by: Ekaterina V. Tikhonenko, et al.
Published: (2019-03-01)

New glance at pathogenesis of type 2 diabetes mellitus: incretin and antiincretin systems.
by: Ekaterina Alekseevna Shestakova
Published: (2011-09-01)

Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice
by: Lee J, et al.
Published: (2019-12-01)

DPP-4 inhibitor treatment: β-cell response but not HbA1c reduction is dependent on the duration of diabetes
by: Kozlovski P, et al.
Published: (2017-03-01)

Dipeptidylpeptidase-4 inhibitors in the treatment of diabetes mellitus. Possibilities of cardioprotection
by: Elena Nikolaevna Trunina, et al.
Published: (2011-06-01)

Distinct Identity of GLP-1R, GLP-2R, and GIPR Expressing Cells and Signaling Circuits Within the Gastrointestinal Tract
by: Nadya M. Morrow, et al.
Published: (2021-09-01)

Insulin Secretion and Incretin Hormone Concentration in Women with Previous Gestational Diabetes Mellitus
by: Sung Hoon Yu, et al.
Published: (2011-02-01)

Clinical factors associated with the occurrence of nausea and vomiting in type 2 diabetes patients treated with glucagon‐like peptide‐1 receptor agonists
by: Megumi Shiomi, et al.
Published: (2019-03-01)

Cannot write session to /tmp/vufind_sessions/sess_9lj2lhp2ufmkff43e9pj1ned0b